 Η πραγματική στιγμή της δεξάμεθος was a progression-free survival and it was met because in the control arm in the protegeum in the methexamethosone arm the median progression-free survival was 9.46 months whereas in the selinexor protegeum in the methexamethosone arm it was 13.93 months. Η δεξάμεθος was statistically significant with the p-value of less than 0.01 and a hazard ratio of 0.7. Περδερμόρ, there was a higher overall response rate associated with SVD at 74.6% versus 62.3% associated with VD. The most frequent treatment related adverse events were cytopenias. For example, there was a grade 3 or 4 thrombocytopenia in 40% of the patients treated with SVD, anemia, gastrointestinal toxicity such as nausea and diarrhea which were mostly grade 1 or 2. Cytopenias were not severe and the bleeding events and the episodes of neutrophinic fever were low so there was a higher incidence of adverse events in the triplet in the SVD arm. However, the occurrence of really severe adverse events that necessitated treatment discontinuation was low so this is why we have approximately the same treatment discontinuation in both arms. Of course we know that there are fewer hospital visits or visits to the clinic to receive the subcutaneous cortezomib and we know that there is less peripheral neuropathy associated with one squiggly cortezomib, less frequent hospital clinic visits so this is associated with an improved quality of life. It was of interest to see that in this particular trial patients who are considered to have high resettles genetics such as patients with 17p deletion or patients who have for 14-thousand locations, 14-16th-thousand locations and other abnormalities did better, performed better with the triplet. τρύπλετ. We know that for this particular patient population we are in constant need to find more active regimens, so this is an additional benefit of the study to show that there was a benefit which was even greater for patients with 17p deletion with the addition of selinexor to proteasomy and hexamethasone. Yes, selinexor has a completely different mechanism of action than other drugs and when it is used once weekly at the lower dose there is a better tolerability because we know that the major limitation of the use of selinexor is the gastrointestinal toxicity of the drug. As we use more and more selinexor we learn how to prevent or to treat this side effect so I believe that having a class of agents that has a different mechanism of action from other drugs from immunomodulatory agents from proteasome inhibitors from monoclonal antibodies is a benefit for the treatment of patients with myeloma.